Top Healthcare Agency Networks
DNA, craft, positioning — what each does best, and where DNAi enters
FCB Health → Olixir New York (Omnicom Health)
Rebrand 2025. $370M revenue. 1,072 FTEs. History: 150yr FCB + 40yr FCB Health dominance.
Craft Leader
Network of the Year 2025
DNA & Philosophy
- "Fearless creators who stop at nothing to improve lives"
- Spark understanding → shift mindsets → drive impact
- Cause-as-strategy: pro bono work that builds agency reputation
- AI-enabled via Omnicom Health infrastructure
Signature Campaigns
- Disappearing Doctors (7+ yrs): physician suicide crisis. Forum on Sermo → 4,500 doctors responded in 48h.
- The Trial for #ClinicalEquality (5+ yrs): racial disparity in clinical trials
- Snowball (SAFE Project): anti-opioid awareness
What they do best
Long-form cause campaigns that sustain across years. The HCP as human — burnout, mental health, systemic barriers. Craft that wins awards AND changes real behavior.
DNAi Gap Opportunity
1,072 people = massive overhead. Mid-size pharma can't access this. DNAi delivers equivalent craft without the holding company pricing or 12-week lead time.
McCann Health (IPG Health Network)
mccannhealth.com now redirects to ipghealth.com. 17% revenue growth in 2024. Launched EPICC platform.
DNA & Philosophy
- Science + strategy + creativity to understand covert drivers of human behavior
- Behavioral change as the north star — HCP, patient, policymaker
- EPICC: end-to-end proprietary platform for insights, creativity, content (2024)
- Strong in Managed Markets: access, formulary, payer influence
Cannes Reference Cases
- Mis[s]Diagnosed (Organon, McCann Dubai) — women receiving wrong diagnoses
- Not a Lonely Journey (Biogen, VML) — rare disease community support
- McCann Health Managed Markets: Agency of Year 2025 (PharmaLive)
What they do best
Why HCPs prescribe the way they do. Data as creative driver. Rare disease with small prescriber universes. Market access strategy embedded in creative.
Publicis Health (Publicis Groupe)
8,000+ specialists. 40+ countries. The network Reeve's training is calibrated against.
Network Structure
| Agency | Specialty |
|---|---|
| Saatchi & Saatchi Wellness | DTC, consumer health, wellness positioning |
| Digitas Health | Digital-first, data-driven, HCP digital |
| Razorfish Health | Tech + experience design |
| Heartbeat | HCP digital engagement |
| Langland | Medical communications, UK-based |
| Publicis Health Media | Specialized media planning + buying |
DNA
- "Making Health Happen"
- Turn challenges into change | Communicate with care | Demystify the difficult
- Proprietary AI ecosystem: dynamic audience design + predictive intelligence + generative creativity
- 2025: 25 new clients, 700+ hires, 61 creative wins worldwide
Reference Work
- Trelegy "Breathing is Beautiful" (GSK, Digitas Health) — breaks typical pharma ad mold
- Working with Cancer (Publicis Conseil) — Cannes Grand Prix for Good 2023
- Eosinophilic esophagitis awareness (Takeda, Saatchi Wellness)
What they do best
Global scale + data intelligence. Medical communications with scientific rigor. Network effect: different specialized agencies collaborate on one client seamlessly.
TBWA\WorldHealth (TBWA Worldwide)
Repositioned from "health agency" to "first agency committed to health impact." Disruption framework applied to healthcare.
Health Impact Model
- Health Impact = Business Impact + Human Impact (not one, both)
- Disruption framework: challenge status quo before building new convention
- "Doesn't look like anyone else. Doesn't function like anyone else."
- Inclusions Strategy Framework — dedicated strategist for inclusive work
- Heavy investment in data practice + AI for measurable outcomes
Reference Work
- "Ashe Versus" (Moderna + Arthur Ashe Foundation) — short film, historical changemakers
- PERIOD campaign — menstrual health access + affordability
- TBWA\Health Collective: joint unit with TBWA\Chiat Day NY for cross-category creative
What they do best
Consumer agency thinking applied to health. Disruption as a real operational framework, not a tagline. Work that earns coverage beyond the trade press. Partnerships outside healthcare (foundations, cultural institutions).
Agency Quick-Reference Matrix
Reeve's mental model for competitive positioning
| Agency | Primary Strength | Best For | Watch Out |
|---|---|---|---|
| Olixir/FCB Health | Pro bono cause campaigns, HCP-as-human, long-running platforms | Large pharma, awareness campaigns with 3-5yr horizon | Overhead. Mid-size pharma priced out. |
| McCann Health | HCP behavioral change, managed markets, rare disease | Specialty Rx, payer strategy, NBRx conversion | Complex network structure. Slow on fast-turn assets. |
| Publicis Health | Scale, data intelligence, medical communications rigor | Global launches, multi-TA portfolios, scientific storytelling | Big pharma only. Process-heavy. Cost prohibitive. |
| TBWA\WorldHealth | Disruption, earned media, consumer crossover campaigns | Disease awareness, OTC/wellness-adjacent, cultural relevance | Less deep on regulatory. More consumer than scientific. |
| Area23 (IPG) | Constraint as creative fuel, Cannes-winning craft | HCP-heavy, rare disease, congress presence, innovative formats | 57 accounts = spread thin. See separate analysis file. |
| DNAi | Publicis-grade quality + AI speed + mid-size accessibility | Mid-size pharma, biotech launches, specialty Rx, BR+USA | Building track record. Scale is a perception challenge. |
Cannes Lions — Grand Prix Winners
Pharma & Health/Wellness category — what won, why, and the transferable insight
Make Love Last — Viagra (Viatris) / Ogilvy Shanghai
Pharma Grand Prix — Cannes Lions 2025
Grand Prix
2025
Three real couples. Long-exposure photography over 4 hours (= Viagra's effectiveness window). Intimate movement captured as abstract light trails. No product name shown — only a blue diamond silhouette near the end. Launched on Chinese Valentine's Day via social + influencers. 350 million total impressions.
The Insight: In China, pharma DTC is banned and intimacy is culturally taboo. Ogilvy Shanghai turned double regulation into a creative brief: "How do you say everything without saying a word?" Answer: hide it in plain sight. Real couples. Real emotion. Symbolic timing. The product claim lives in the concept, not the copy.
Lesson for Reeve
Regulatory restriction is not the enemy — it's the brief. The tighter the constraint, the more specific the creative must be. Generic ideas don't survive constraint; specific ideas thrive in it.
Magnetic Stories — Siemens Healthineers / Area23 (IPG Health)
Pharma Grand Prix — Cannes Lions 2024
Grand Prix
2024
Bestselling authors commissioned to write audiobooks where MRI sounds (clanging, whirring, banging) were incorporated as story sound effects. The terrifying machine noise becomes a robot, a spaceship, an adventure. Children enter the scanner already in the story world.
The Insight: The problem IS the solution. The anxiety-inducing sounds of an MRI machine are the raw material for creating wonder. Product and creative are not separate — they are the same thing.
Lesson for Reeve
The biggest creative opportunities are hiding inside the product's most uncomfortable truths. What's the MRI noise in your brief?
Scrolling Therapy — Eurofarma (Parkinson's) / Dentsu Creative
Pharma Grand Prix — Cannes Lions 2023
Grand Prix
2023
App enabling Parkinson's patients to scroll social media using facial expressions. Facial expression recognition turns social media browsing into continuous motor therapy. Launched in 10 countries. 1B+ earned media impressions. 88% engagement rate.
The Insight: Therapy requires repetition. Repetition requires habit. Habit requires desire. The therapy was embedded inside something people already wanted to do — social media. Meet patients where they are, not where you think they should be.
Health & Wellness — Grand Prix
Not pharma-specific, but the strategic benchmarks that define category excellence
Vaseline Verified — Vaseline (Unilever) / Ogilvy Singapore + UK + Edelman
Health & Wellness Grand Prix — Cannes Lions 2024 + 2025
Vaseline scientists lab-tested viral social media skin care "hacks" from TikTok creators. Hacks that worked earned an official "Vaseline Verified" trophy. Dangerous hacks were debunked via out-of-home advertising. Co-branded with Flamin' Hot on a heat hack.
The Insight: UGC health content is uncontrollable — so own the fact-checking. Scientific authority + social relevance = brand as trusted friend, not corporate voice. The brand becomes the curator, not the broadcaster.
The Last Performance — Partners Life / Special New Zealand
Health & Wellness Grand Prix — Cannes Lions 2023
Life insurance ads appeared at the end of each episode of NZ TV drama "The Brokenwood Mysteries" — featuring characters who had been killed off in the show. Dead characters convincing viewers to get life insurance. +135% website traffic. +75% direct leads. +26% brand awareness.
The Insight: The most powerful media is the media that already has attention. Existing programming was repurposed as the creative vehicle. Entertainment and advertising became the same thing. The jury said: "So good viewers actually want to watch it rather than skip it."
Lesson for Reeve
Format as idea. The medium IS the message. What pre-existing attention can a healthcare brand borrow instead of fighting for?
Lions Health Grand Prix for Good
Make NZ The Best Place to Have Herpes 2025
NZ Herpes Foundation / Motion Sickness. Celebrities, Herpes Stigma Index for 10 OECD countries. Humor as destigmatization strategy. NZ went from 9th to 1st place in the Index.
Lesson: Humor outperforms fear in stigma reduction. Always.
Working with Cancer 2023
Publicis Groupe + Memorial Sloan Kettering. Cross-industry coalition to eliminate workplace stigma around cancer diagnosis. Purpose work at systemic scale.
Lesson: The most awarded purpose work solves a systemic problem, not a brand problem.
Launch Case Studies
Strategic deep-dives for campaign reference
TZIELD (teplizumab-mzwv) — Sanofi/Provention Bio
FDA approved November 2022. First drug to delay T1D Stage 3. Active DNAi project.
HCP Messaging Architecture
- Core claim: "ACT WITHIN THE WINDOW" — timing is the product
- "First innovative biologic in T1D since insulin 100 years ago"
- Target: pediatricians + endocrinologists + PCPs with T1D patients
- Data: TN-10 trial (NEJM), PETITE-T1D (safety, ages 1-8)
- Screening messaging: consensus guidelines on islet AAb testing
- Resources: Talking T1D Podcast, COMPASS HCP portal, administration guides
DTC/Patient Messaging
- Headline: "Reshape your journey with type 1 diabetes"
- Hook: "A chance to get more time before Stage 3 T1D"
- Journey mapped: Unaware → Screened → Diagnosed Stage 2 → Treated → Supported
- COMPASS support program: navigator + access + copay + reimbursement
- Tone: empowerment via preparation, not fear
- Visual: family moments, authenticity over staged stock
Strategic Challenge
The primary mission is category creation — "Stage 2 T1D" doesn't exist in most people's vocabulary. Disease awareness must precede and sustain branded messaging. Screening is the access funnel. No screening = no patient. The emotional insight: time is the product. Every month of delay is tangible, real gain.
Commercial Context
Sales slow at launch, doubled to €54M in 2024, +€47M first 9 months of 2025. Still a market education challenge more than a demand challenge. The opportunity: DNAi can accelerate screening behavior and HCP urgency framing.
Dupixent (dupilumab) — Sanofi/Regeneron
Launched March 2017 (atopic dermatitis). Expanded to asthma, EoE, DPOC, PN. One of pharma's biggest launches ever.
Why It Worked — 5 Principles
1
Patient insight, not agency insight
The insect/crawling imagery came directly from patient research — patients described eczema itch as "insects crawling on skin." Authentic because it was theirs, not invented.
2
Indication ladder = DTC ladder
Each new FDA approval (asthma, EoE, DPOC) opened new DTC campaign. Strategy of continuous expansion kept brand top-of-mind for 8 years.
3
Humor as mechanism, not decoration
"Du More" (asthma): insight that patients see doctors to "breathe better so they can DO things." Humor in life scenarios + breathing = highest tested concept in brand history. Entertainment value drives doctor discussion rate.
4
Sustained investment, not campaign
$287.6M in DTC spend in 2021 alone. #1 pharma DTC spender for multiple years. A platform built over years, not a campaign cycle.
5
DTC-HCP alignment
20% increase in patient-initiated doctor discussions. DTC prepares the patient. HCP is already briefed. Conversion happens when both moments align simultaneously.
Keytruda (pembrolizumab) — Merck
Launched 2015 (NSCLC). Became #1 immuno-oncology drug globally. DTC in oncology was controversial — Merck did it right.
Strategy
- Phase 1: HCP-only. Journal ads, MSLs, scientific credibility. No mass market rush (contrast: BMS went DTC fast with Opdivo).
- Phase 2: DTC with "Living Longer Is Possible" — hope grounded in data
- Real patient (Donna, Stage 4 NSCLC) as protagonist. Authenticity non-negotiable.
- Real oncologist (Dr. Kloecker) in ads — clinical credibility, not actor in white coat
Dual-Audience Insight
Critical Oncology Dynamic
DTC ads also reach oncologists. When an oncologist knows that their patients are seeing the DTC and will ask about the drug, that alone creates motivation to consider prescribing. The "patient asks doctor" moment is anticipated by the HCP even before the patient arrives.
MM+M Awards 2024 — USA Benchmark
Key winners and what they signal about the industry
Winners
- Healthcare Network of the Year (Gold): Real Chemistry — AI-powered insights into client-centric marketing
- Midsize Agency of the Year (Gold): /Prompt
- Med Comms Agency of the Year (Gold): Inizio Medical
- Consumer Media Brand (Gold): HealthCentral (3rd consecutive year)
- Notable campaign: Nick Jr. x Sanofi/Regeneron x National Eczema Association — Blue's Clues character for eczema education (Dupixent ecosystem)
What This Signals
- AI-powered insights are now table stakes for agency differentiation
- Mid-size agencies winning — the field is leveling
- Children's media partnerships for patient education = underutilized creative space
- Network of the Year went to a tech-first agency (Real Chemistry), not a classic creative shop
OPDP — Office of Prescription Drug Promotion
The regulatory body that reviews, monitors, and enforces pharma advertising in the USA
2025 Enforcement Crackdown — CRITICAL
September 2025: FDA + HHS jointly announced enforcement crackdown on deceptive DTC advertising, including social media influencers. ~100 cease-and-desist orders. Thousands of warning letters. FDA stated "deceptive advertising is sadly the current norm on social media." Initiated rulemaking to close the 1997 "adequate provision" loophole. OPDP issued 25 enforcement letters in Q1 2025 alone — 2x same period prior year.
OPDP Enforcement Tools
- Untitled Letters (IHCTOA): Violations not rising to warning-letter significance
- Warning Letters: Violations of regulatory significance — public, searchable
- Cease-and-Desist: Stop all promotional activity immediately
What OPDP Monitors
- All broadcast DTC (TV, radio)
- Print advertising (journal ads, consumer magazines)
- Digital and websites
- Social media (brand accounts + influencers acting on behalf of brand)
- HCP promotional materials
- Speaker program content
Fair Balance — The Complete Rulebook
The non-negotiable framework behind every piece of pharma creative
Core Legal Standard
Risk information must have "comparable prominence" to benefit information. It cannot be buried in fine print, rushed through voiceover, or hidden behind a link. The Net Impression Test applies: if the ad leaves viewers with a stronger impression of benefit than risk, it can be misleading even when safety language is technically present.
2024 Broadcast Rule (Effective Nov 20, 2024)
- Consumer-friendly language (not medicalese)
- Audio "at least as understandable as the rest of the ad"
- TV: presented simultaneously in audio AND text
- Proper font choice, contrast, and placement for text
- No audio/visual elements interfering with comprehension of major statement
6 Violation Patterns FDA Catches
1
Placement IssuesSafety in collapsed sections, sticky trays, or footer areas while benefits dominate hero sections.
2
Readability FailuresSmall type, low contrast, dense paragraphs for risk vs. large, clean typography for benefit.
3
Pace MismatchBenefit segments feel human and relaxed. Risk segments become fast, compressed, harder to hear.
4
Visual InterferenceMajor statement paired with dramatic imagery, humor, emotional storytelling, or fast edits that pull attention away.
5
Off-Page Reliance"Learn about side effects" links as the primary safety mechanism. FDA signaled this approach is losing credibility.
6
Social ImbalanceA 2024 scoping review found 100% of DTC social posts included benefits, while only 33% mentioned harms.
ISI — Important Safety Information
How fair balance is implemented in digital assets
ISI Digital Rules
- Efficacy claims placed near relevant safety context
- ISI readable on desktop AND mobile
- Repeated benefit claims = proportionally repeated safety language
- Overall experience must leave balanced net impression
- Email: fair balance covers subject line + hero + CTA + landing page behavior
Formats
- Brief Summary: Print ads — summary of PI on same or adjacent page
- Full PI: For professional audiences, prescribing information
- Truncated ISI: Digital use — key risks, links to full PI
- Major Statement: Broadcast — most significant risks + important use info
Social Media Pharma Compliance
Platform-by-platform rules for 2026
| Platform | Requirements | Key Restrictions |
|---|---|---|
| Meta/Instagram | LegitScript certification; manufacturer pre-approval; US/Canada/NZ only | No targeting under 18; privacy-safe measurement mandatory |
| Prior authorization needed | No targeting by health data; restricted for Rx drugs and medical devices | |
| X/Twitter | Prior authorization US/Canada | Many health categories prohibited; limited pharma ad support |
| TikTok | Market-specific rules; FDA proof required; 18+ targeting in US | Prescription drug ads often disallowed; enforcement increasing |
| YouTube/Google | Certification required; same fair-balance rules as traditional media | Location-specific restrictions; ongoing policy updates |
The Golden Rule — Non-Negotiable
If fair balance, context, and risk cannot be presented clearly and reviewably on the platform itself, the asset should not run. Platform approval is separate from FDA compliance. One-click-away safety info is being eliminated as acceptable practice.
Influencer Content — Full Promotional Burden
- If creators speak on behalf of the brand, all promotional rules apply
- Scripts, captions, overlays, and link behavior = regulatory communications
- Content feeling "native" doesn't reduce compliance burden
- AI-generated content variants must meet same standards as human-created copy
- Misinformation corrections: must remain factual and non-promotional — never use corrections as sales moments
Regulatory Vocabulary — Operational Reference
Terms Reeve must have internalized. Use precisely in every client conversation.
| Term | Definition | Why It Matters |
|---|---|---|
| PI (Prescribing Information) | The official FDA-approved product document. The source of truth. | No claim can go beyond what's in the PI. Ever. |
| On-label | Promotion within the approved indication, population, dose, route. | Everything in the ad must be on-label. |
| Off-label | Promoting for unapproved use, population, dose, or route. | Illegal in marketing. Prosecutable offense. |
| Indication Statement | The exact FDA-approved indication sentence. | Must appear in every promotional piece. |
| ISI | Important Safety Information — subset of PI risks for ad use. | Design and content component for all digital assets. |
| Brief Summary | Summary of full PI required in print ads. | 1-page rule for print — same or adjacent page. |
| Major Statement | Most significant risk + most important use info in broadcast DTC. | Now must be audio + text simultaneously (2024 rule). |
| Fair Balance | Risk presented with comparable prominence to benefit. | The governing principle of all pharma promotion. |
| OPDP | Office of Prescription Drug Promotion. | The FDA branch that reviews and enforces. |
| MLR | Medical, Legal, Regulatory review process. | Every promotional piece must pass before use. |
| NRx | New prescriptions (including switches from competitor). | Key metric for brand growth. |
| TRx | Total prescriptions (NRx + refills). | Volume metric for market share. |
| NBRx | New-to-brand prescriptions. | Purest measure of marketing-driven trial. |
| KOL | Key Opinion Leader — high-influence prescribers. | Shape peer opinion. Targets for speaker programs. |
| MSL | Medical Science Liaison — scientific field force. | Cannot make commercial pitch. Educates clinically. |
DTC vs HCP — Decision Framework
When to lean one direction vs the other, and why
Direct-to-Consumer (DTC)
- Formulary coverage >70% commercial plans
- Low patient out-of-pocket cost
- Low disease/treatment awareness in target patients
- Primary care product (broad HCP universe)
- Vaccines and OTC-adjacent products
Dominant Message Theme
Lifestyle benefits, symptom relief, identity reclamation, hope. Copay support. "Talk to your doctor about X."
Healthcare Professional (HCP)
- Prior authorization or step therapy required
- Specialty product (limited prescriber universe)
- Rare disease (<500 treating physicians total)
- New product category (needs clinical education first)
- Oncology and high-science categories
Dominant Message Theme
Clinical evidence, MOA, efficacy data, safety profile, dosing, patient selection criteria, formulary access.
Budget Allocation Benchmarks by Therapeutic Area
| Therapeutic Area | HCP % | DTC % | Rationale |
|---|---|---|---|
| Oncology | 70% | 30% | Oncologist drives decision; DTC builds patient conversation |
| Primary Care Cardiology | 50% | 50% | Both HCP and patient influence prescription |
| Rare Disease | 85% | 15% | Tiny patient population; HCP identification is the funnel |
| Vaccines | 40% | 60% | Consumer demand drives administration |
| T1D (TZIELD-type) | 65% | 35% | Screening-dependent; HCP must ID Stage 2 patients |
The Integration Imperative
DTC-HCP misalignment reduces conversion from 68% to 41% industry benchmark. When brands guide both sides of the prescription conversation with aligned messaging, they build clinical confidence and consumer demand simultaneously. They must speak with one voice.
Patient Journey Map — 6-Stage Framework
The operational model for timing and targeting all communications
1
UNAWARE
Has symptoms but hasn't connected them to a condition. Doesn't know a treatment exists.
Channel: Disease awareness (unbranded), search, consumer social. KPI: Reach, symptom search volume, brand recall.
Channel: Disease awareness (unbranded), search, consumer social. KPI: Reach, symptom search volume, brand recall.
2
AWARE / SYMPTOMATIC
Recognizes symptoms, actively seeking information.
Channel: Paid search, endemic health sites (WebMD, Healthline), social. KPI: Website visits, condition content engagement, symptom keyword performance.
Channel: Paid search, endemic health sites (WebMD, Healthline), social. KPI: Website visits, condition content engagement, symptom keyword performance.
3
SEEKING DIAGNOSIS
Actively looking for clinical validation. Searching for doctors.
Channel: Physician finder tools, unbranded patient programs, HCP awareness activation. KPI: Doctor discussion rate, diagnosis rate in target population.
Channel: Physician finder tools, unbranded patient programs, HCP awareness activation. KPI: Doctor discussion rate, diagnosis rate in target population.
4
DIAGNOSED / CONSIDERING TREATMENT
Has diagnosis. Evaluating options. This is where branded DTC and HCP coordination must peak.
Channel: Branded DTC, HCP detail, patient community, copay program. KPI: New patient starts, copay enrollment, NBRx.
Channel: Branded DTC, HCP detail, patient community, copay program. KPI: New patient starts, copay enrollment, NBRx.
5
ON TREATMENT
Started therapy. The adherence battle begins.
Channel: Patient support programs, adherence SMS/email, refill reminders, nurse educators. KPI: 90-day refill rate, 12-month adherence, time on therapy.
Channel: Patient support programs, adherence SMS/email, refill reminders, nurse educators. KPI: 90-day refill rate, 12-month adherence, time on therapy.
6
ADHERENT / ADVOCATE
Long-term patient. Potential ambassador. High lifetime value.
Channel: Patient ambassador programs, peer support communities, social testimonial. KPI: NPS, ambassador pipeline, peer referral rate.
Channel: Patient ambassador programs, peer support communities, social testimonial. KPI: NPS, ambassador pipeline, peer referral rate.
HCP Segmentation — Prescriber Targeting Framework
Beyond decile thinking — how elite teams target HCPs
Standard Decile Model
Prescribers ranked 1-10 by category TRx over rolling 52 weeks. Decile 10 = top 10% of writers in category. Field force focuses on high deciles. Digital covers lower deciles.
The Decile Trap
A decile-8 who has never prescribed your brand is a different target than a decile-5 who just wrote 3 NBRx last month. Volume ≠ opportunity.
Double-Decile Methodology
Adds a second dimension: digital affinity (likelihood HCP will respond to digital channels). Rank by Rx potential CROSSED with digital receptivity. Focus field force where potential is high + digital won't work. Focus digital where potential is moderate + HCP is online.
Behavioral Segments
| Segment | Behavior | Strategy |
|---|---|---|
| Dominant | Prescribes primarily 1-2 drugs in category | Hard to switch. Need strong differentiation message or major patient event. |
| Dual | Alternates between 2 drugs regularly | Best target for NBRx conversion. Already open to your brand. |
| Spreader/Erratic | No consistent prescribing pattern | Educate on patient selection. Create a clear mental model for "when to prescribe." |
| Non-writer | In category but doesn't prescribe | Identify barrier: access? awareness? patient population mismatch? |
Data Sources
- IQVIA / Symphony Health: Prescribing data, Rx panels
- Doximity / Medscape: HCP digital engagement data
- CRM: First-party rep call history
- EHR data: Real-world data for patient population insights
MLR Review — Creative Survival Guide
How to navigate Medical, Legal, Regulatory without killing the idea
M — Medical
- Scientific accuracy of all claims
- Every claim must have data support (cited study)
- Correct medical terminology
- No off-label implications
- Balance of efficacy vs. safety presentation
L — Legal
- IP and trademark compliance
- Competitive claims and litigation risk
- Fair balance from legal liability angle
- PhRMA Code compliance (HCP gifts, meals, travel)
- Privacy and patient consent for testimonials
R — Regulatory
- FDA/OPDP compliance
- Fair balance adequate per format
- ISI correct and complete
- Claims within approved label (PI)
- Format-appropriate requirements met
Systems
- Veeva Vault PromoMats (industry standard)
- Zinc — for digital/social workflows
- Archive all assets, placements, revisions
- Separate workflows: social, influencers, video, off-label response, adverse events
5 Rules for Keeping Creativity Alive in MLR
1
Bring Medical into the brief, not the finish
Pre-MLR conversation with Medical Affairs before creative is written. Know which claims are defensible before the team invests in them.
2
Build a pre-approved claims library
Bank of claims already reviewed by Medical. Every new asset draws from this bank. Eliminates the "can we say this?" loop on every deliverable.
3
Constraint IS the brief
Present regulatory restrictions to creatives as part of the creative brief, not as an afterthought. The Cannes winners that got it right treated regulation as the fuel, not the brake.
4
MLR is protecting patients, not blocking art
Shared goal is the patient. When MLR sees the creative team understands that, collaboration opens up. When creative treats MLR as the enemy, the relationship closes.
5
Document roles, not just content
SOPs defining who reviews what, in what order, with what turnaround. Ambiguity in process kills speed and sometimes kills campaigns. Clarity in process protects the creative.
Message Architecture — The 4-Layer Model
How to build from approved claim down to emotional execution
CORE CLAIM (on-label, MLR-approved, one sentence)
↓
PROOF POINTS (clinical data supporting the core claim — 3 max)
↓
RTBs — REASONS TO BELIEVE (MOA, differentiation, safety profile, access)
↓
EMOTIONAL TERRITORY (how this translates to real life — patient or HCP)
↓
CREATIVE EXECUTION (the campaign idea that makes the emotional territory visceral)
HCP Message Hierarchy
- Core: Efficacy + safety (primary trial data)
- Proof: NNT, clinical outcomes, durability, comparators
- RTB: Differentiated MOA, safety profile, formulary access, dosing convenience
- Emotional: "Confidence to prescribe" — changing expectations for patients
DTC Message Hierarchy
- Core: What the product does — translated to patient relevance
- Proof: What to expect (human language, not medicalese)
- RTB: Ease of use, support program, copay, access
- Emotional: Life reclaimed, identity restored, hope that is possible — not promised
Pre-Launch Market Shaping Framework
The phases that determine whether a launch wins or fails at Year 1
Validated Benchmark
Top-performing launches invest nearly 2x more in pre-launch activities vs. competitors. Start 12-24 months before approval. Initiate commercial advisory boards ~1 year before FDA approval.
1
Scientific Seeding (24-18 months pre-launch)
KOL engagement, advisory boards, Phase III data publication. Build scientific credibility before commercial machinery activates.
2
Disease Education — Unbranded (18-12 months)
Educate HCPs and patients about the disease, staging, unmet need. No product name. Establish vocabulary. Build market receptivity.
3
Category Creation (12-6 months)
Signal that a solution exists. Build anticipation. KOL talks at congress about the mechanism class without naming the brand.
4
Brand Reveal (6 months - launch)
Product enters a market already shaped to receive it. Branded messaging builds on the vocabulary and urgency already created.
5
Post-Launch Amplification (Year 1)
DTC + HCP fully integrated. Patient support programs active and promoted. COMPASS-type programs driving adherence and access.
DNAi Global AI Studio — Healthcare Positioning
Where DNAi enters the competitive map. How Reeve articulates the value proposition.
The Core Proposition
Publicis-grade creative and regulatory intelligence + AI speed at boutique cost. We work where the big agencies won't, and we move at the speed that launches demand.
| Dimension | Big Holding Agency | DNAi Global AI Studio |
|---|---|---|
| Creative Quality | Publicis / IPG-grade | Same — Reeve calibrated against Publicis NY |
| Speed | 6-12 weeks per deliverable | 1-3 weeks |
| Cost | $350K-$1M+ per campaign | Mid-size pharma accessible |
| AI Integration | Tool, not strategy | Core competency + differentiator |
| Regulatory Depth | Dedicated MLR teams | Reeve — senior FDA expertise embedded |
| Market Access | Big pharma only | Mid-size pharma + biotech + medtech |
| Personalization | Limited by overhead | Granular via AI — HCP targeting at scale |
| Global | Network of subsidiaries | Brazil + USA native — both markets |
| Scientific Synthesis | Manual med writers | AI-accelerated literature to content pipeline |
Ideal DNAi Healthcare Clients
Where to focus commercial energy
Primary Targets
- Biotech mid-size with Phase III readout or NDA filing — needs pre-launch market shaping
- Specialty pharma with approved product and $500K-$2M campaign budget
- Medtech device (510k/De Novo) needing B2B hospital launch
- International pharma entering USA for first time — needs FDA regulatory intelligence + creative
What They Need That DNAi Delivers
- Pre-MLR claim strategy so creative doesn't die in review
- HCP segmentation without paying IQVIA agency markups
- Patient journey mapping for rare disease where no playbook exists
- Disease awareness campaigns in 3 weeks, not 3 months
- AI-synthesized clinical evidence into HCP-ready content
Gaps Identified in Competitive Landscape
Where every major agency leaves room — where DNAi enters
| Gap Identified | Agency Failing | DNAi Solution |
|---|---|---|
| Mid/small pharma under-served | 1,000+ person agencies = overhead too high for $1M client | Publicis-grade output at studio pricing |
| AI as tool, not competency | All agencies use AI in production but none position it as strategic differentiator | AI is DNAi's core — not a feature, the product |
| HCP personalization at scale | Traditional agencies personalize by specialty at best | AI enables behavior-based personalization across 100+ HCP segments |
| Clinical evidence → content velocity | Med writers are slow and expensive | AI processes literature → HCP content in fraction of time |
| Multi-regulatory global | US agencies don't understand ANVISA; Brazilian agencies don't understand FDA | DNAi is BR + USA native — cross-regulatory expertise |
| Patient journey agents | No agency offers AI-driven patient support automation | DNAi builds agents for adherence, screening, access navigation |
Reeve's Creative Operating Principles
The non-negotiables that define quality at DNAi Healthcare
01 / Clarity First
Clarity before beauty. In healthcare, confusion kills. Literally. If the audience can't understand the message in one read, the creative failed.
02 / Authentic Human
Patient as protagonist, not as illustration. Real moment, specific detail, earned emotion. Zero generic stock photography of smiling people on beaches.
03 / Constraint as Brief
FDA regulation is not the enemy. It's the brief. Every Cannes Grand Prix in pharma won because the creative team understood the constraint and found the unexpected within it.
04 / Format as Idea
The medium is part of the message. Audiobooks for MRI. TV drama characters for life insurance. What pre-existing behavior or format can carry the strategy?
05 / Audience Precision
Always ask: HCP or patient? What specialty? What behavioral segment? What point in the journey? The answer changes everything about the creative approach.
06 / No Sentimental
Humanity without sentimentalism. Healthcare audiences are smart and have seen every tearjerker. Specific and real wins over broad and emotional every time.
Related Files — Load Per Campaign
/opt/AGENTE/memory/reeve-area23-analise.md— Area23/IPG Health competitive analysis (Cannes Grand Prix: Magnetic Stories, Unwearable Collection, Lil Sugar)/opt/AGENTE/memory/reeve-knowledge-base.md— This file in markdown (for agent memory loading)/opt/AGENTE/memory/projects.md— Active campaigns including TZIELD